BACKGROUND: We sought to determine the prognostic value of pathologic response to neoadjuvant chemotherapy with concurrent trastuzumab. PATIENTS AND METHODS: Two hundred and twenty-nine women with HER2/neu (HER2)-overexpressing breast cancer were treated with neoadjuvant chemotherapy plus trastuzumab between 2001 and 2008. Patients were grouped based on pathologic complete response (pCR, n = 114) or less than pCR (<pCR, n = 115); as well as by pathologic stage. Locoregional recurrence-free (LRFS), distant metastasis-free (DMFS), recurrence-free (RFS), and overall survival (OS) rates were compared. RESULTS: The median follow-up was 63 (range 53-77) months. There was no difference in clinical stage between patients with pCR or <pCR. Compared with patients achieving <pCR, those with the pCR had higher 5-year rates of LRFS (100% versus 95%, P = 0.011), DMFS (96% versus 80%, P < 0.001), RFS (96% versus 79%, P < 0.001), and OS (95% versus 84%, P = 0.006). Improvements in RFS and OS were seen with decreasing post-treatment stage. Failure to achieve a pCR was the strongest independent predictor of recurrence (hazard ratio [HR] = 4.09, 95% confidence interval [CI]: 1.67-10.04, P = 0.002) and death (HR = 4.15, 95% CI: 1.39-12.38, P = 0.011). CONCLUSIONS: pCR and lower pathologic stage after neoadjuvant chemotherapy with trastuzumab are the strongest predictors of recurrence and survival and are surrogates of the long-term outcome in patients with HER2-overexpressing disease.
BACKGROUND: We sought to determine the prognostic value of pathologic response to neoadjuvant chemotherapy with concurrent trastuzumab. PATIENTS AND METHODS: Two hundred and twenty-nine women with HER2/neu (HER2)-overexpressing breast cancer were treated with neoadjuvant chemotherapy plus trastuzumab between 2001 and 2008. Patients were grouped based on pathologic complete response (pCR, n = 114) or less than pCR (<pCR, n = 115); as well as by pathologic stage. Locoregional recurrence-free (LRFS), distant metastasis-free (DMFS), recurrence-free (RFS), and overall survival (OS) rates were compared. RESULTS: The median follow-up was 63 (range 53-77) months. There was no difference in clinical stage between patients with pCR or <pCR. Compared with patients achieving <pCR, those with the pCR had higher 5-year rates of LRFS (100% versus 95%, P = 0.011), DMFS (96% versus 80%, P < 0.001), RFS (96% versus 79%, P < 0.001), and OS (95% versus 84%, P = 0.006). Improvements in RFS and OS were seen with decreasing post-treatment stage. Failure to achieve a pCR was the strongest independent predictor of recurrence (hazard ratio [HR] = 4.09, 95% confidence interval [CI]: 1.67-10.04, P = 0.002) and death (HR = 4.15, 95% CI: 1.39-12.38, P = 0.011). CONCLUSIONS: pCR and lower pathologic stage after neoadjuvant chemotherapy with trastuzumab are the strongest predictors of recurrence and survival and are surrogates of the long-term outcome in patients with HER2-overexpressing disease.
Entities:
Keywords:
HER2; breast cancer; neoadjuvant chemotherapy; pathologic complete response; trastuzumab
Authors: D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: H M Kuerer; L A Newman; T L Smith; F C Ames; K K Hunt; K Dhingra; R L Theriault; G Singh; S M Binkley; N Sneige; T A Buchholz; M I Ross; M D McNeese; A U Buzdar; G N Hortobagyi; S E Singletary Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: Aman U Buzdar; Nuhad K Ibrahim; Deborah Francis; Daniel J Booser; Eva S Thomas; Richard L Theriault; Lajos Pusztai; Marjorie C Green; Banu K Arun; Sharon H Giordano; Massimo Cristofanilli; Debra K Frye; Terry L Smith; Kelly K Hunt; Sonja E Singletary; Aysegul A Sahin; Michael S Ewer; Thomas A Buchholz; Donald Berry; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2005-02-28 Impact factor: 44.544
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: I Osorio-Silla; A Gómez Valdazo; J I Sánchez Méndez; E York; M Díaz-Almirón; J Gómez Ramírez; S Rivas Fidalgo; J M Oliver; C M Álvarez; D Hardisson; M Díaz Miguel; F Lobo; J Díaz Domínguez Journal: Ann R Coll Surg Engl Date: 2018-11-13 Impact factor: 1.891
Authors: Elizabeth A Mittendorf; Jose Vila; Susan L Tucker; Mariana Chavez-MacGregor; Benjamin D Smith; W Fraser Symmans; Aysegul A Sahin; Gabriel N Hortobagyi; Kelly K Hunt Journal: JAMA Oncol Date: 2016-07-01 Impact factor: 31.777
Authors: Judy C Boughey; Karla V Ballman; Linda M McCall; Elizabeth A Mittendorf; William Fraser Symmans; Thomas B Julian; David Byrd; Kelly K Hunt Journal: Ann Surg Date: 2017-10 Impact factor: 12.969
Authors: R Lesurf; O L Griffith; M Griffith; J Hundal; L Trani; M A Watson; R Aft; M J Ellis; D Ota; V J Suman; F Meric-Bernstam; A M Leitch; J C Boughey; G Unzeitig; A U Buzdar; K K Hunt; E R Mardis Journal: Ann Oncol Date: 2017-05-01 Impact factor: 32.976
Authors: Jashodeep Datta; Erik Berk; Shuwen Xu; Elizabeth Fitzpatrick; Cinthia Rosemblit; Lea Lowenfeld; Noah Goodman; David A Lewis; Paul J Zhang; Carla Fisher; Robert E Roses; Angela DeMichele; Brian J Czerniecki Journal: Breast Cancer Res Date: 2015-05-23 Impact factor: 6.466
Authors: A M Gonzalez-Angulo; N Parinyanitikul; X Lei; E A Mittendorf; H Zhang; V Valero; K K Hunt; G N Hortobagyi; M Chavez-MacGregor Journal: Br J Cancer Date: 2015-01-13 Impact factor: 7.640
Authors: Tamera J Lillemoe; Mara Rendi; Michaela L Tsai; Monica Knaack; Rina Yarosh; Erin Grimm; Barbara Susnik; Janet Krueger; Susan Olet; Karen K Swenson Journal: Int J Breast Cancer Date: 2021-05-24
Authors: V Petry; D M Gagliato; A I C Leal; R J Arai; E Longo; F Andrade; M D Ricci; J R Piato; R Barroso-Sousa; P M Hoff; M S Mano Journal: Braz J Med Biol Res Date: 2015-03-06 Impact factor: 2.590